Keryx initiates clinical trial program for KRX-0401
US firm Keryx Biopharmaceuticals has initiated a corporate-sponsored clinical program for its KRX-0401 (perifosine), a novel, oral AKT inhibitor with potential in the treatment of cancer.
The first trial will be multicentered and will evaluate the safety and efficacy of KRX-0401 as a single agent in patients with non-small cell lung cancer who have progressed despite standard therapy.
The first part of the study will be a short dose escalation phase, designed to build upon a weekly-dosing Phase I trial conducted in Europe which never determined a maximum tolerated dose, while the second stage will enroll an additional cohort of around 20 patients at the MTD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze